More on ABBV
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $254.39 |
|
|||
| Open | $257.00 | ||||
| 52 Wk High | $68.12 | ||||
| 52 Wk Low | $50.71 | ||||
| Day High | $260.96 | ||||
| Day Low | $254.29 | ||||
| P/E | 55.20 | ||||
| EPS | $4.61 | ||||
| Volume | 6,872,636 | ||||
- EU approves AbbVie's Boey for short-duration frown line treatment
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in ad
- Abbvie (ABBV) PT Raised to $260 at Citi
- SkinMedica launches advisory board and expands R&D lab in Irvine
- SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
- Abbvie (ABBV) PT Raised to $300 at BMO Capital
- Abbvie (ABBV) PT Raised to $280 at RBC Capital
- Abbvie (ABBV) PT Raised to $295 at Wells Fargo
- Abbvie (ABBV) PT Raised to $280 at JPMorgan
- Abbvie (ABBV) PT Raised to $261 at Guggenheim
Entities mentioned with ABBV
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Dividend | View Related Stories »
- Show More...
